Form 4: Tarsus Director Gifts 2,000 Shares

Tarsus Pharmaceuticals Director William J. Link gifted 2,000 shares of common stock, as reported in a recent SEC Form 4 filing.

Summary

• William J. Link, a Director of Tarsus Pharmaceuticals, Inc. (TARS), reported a change in beneficial ownership.
• The transaction involved a gift (Transaction Code G) of 2,000 shares of Common Stock.
• The transaction occurred on September 16, 2025, with a reported price of $0 per share.
• Following this transaction, Mr. Link directly owns 141,332 shares of Common Stock.
• Additionally, Mr. Link indirectly beneficially owns 10,446 shares through Link Family Enterprise, LP, where he is the controlling member.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: A gift of shares by a director is generally considered a neutral event for the company's stock price, as it represents a transfer of ownership rather than a sale for liquidity or a purchase indicating increased confidence.

Positives

• The transaction was a gift, not a sale, indicating no direct divestment for personal liquidity.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, suggesting a pre-arranged and systematic approach to share transfers.

Negatives

• No direct negatives are apparent from this gift transaction.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction is a routine disclosure and does not provide specific insights into broader industry trends or the competitive landscape.

Related Party Transactions

• The indirect beneficial ownership of 10,446 shares through Link Family Enterprise, LP, where the reporting person is the controlling member, represents a related party interest.

Stakeholder Impact

• Shareholders: Minimal direct impact on the overall share structure or value due to the relatively small number of shares gifted.
• Company: No direct financial impact from the gift transaction itself.

Key Dates

Recommendation

The filing reports a routine insider transaction involving a gift of shares by a director. This event is neutral in nature and does not provide new material information that would warrant a change in investment recommendation for Tarsus Pharmaceuticals, Inc.

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, insider transaction, stock gift, director, beneficial ownership, William J. Link, Rule 10b5-1